FMT

Fecal microbiota transplantation (FMT) has proven to be an effective treatment for recurrent Clostridioides difficile infection (rCDI) in both adult and pediatric patients. However, as microbiome development is a critical factor in children, it remains unclear whether adult fecal donors can provide …

Molecular Psychiatry - A systematic review exploring the association between the human gut microbiota and brain connectivity in health and disease

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

Decreased muscle mass and function, also known as sarcopenia, is common in patients with cirrhosis and is associated with a poor prognosis. Although the pathogenesis of this disorder has not been fully elucidated, a disordered gut-muscle axis probably plays an important role. Decreased barrier funct …

Therapy for C. difficile infections includes the use of antibiotics, immunosuppressors, and fecal microbiota transplantation (FMT). However, these treatments have several drawbacks, including the loss of colonization resistance, promotion of autoimmune disorders, and the potential for unknown …

The gut microbiome is an indicator of preclinical Alzheimer’s disease (AD) and may improve machine learning prediction of AD status.

In this post-hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications or comorbidities.

These experiments demonstrate substantial and rapid inactivation of representative organisms, supporting the potential benefit of VOS manufacturing processes to mitigate risk.

Fecal microbiota transplantation (FMT) has proven to be an effective treatment for recurrent Clostridioides difficile infection (rCDI) in both adult and pediatric patients. However, as microbiome development is a critical factor in children, it remains unclear whether adult fecal donors can provide …

Should we be considering specific trials investigating #FMT for immunotherapy induced IBD flares/colitis? I bet they are often excluded from FMT trials.— Dr Hannah Rose Wardill (@hannahrwardill) August 3, 2023

Fecal microbiota transplantation (FMT) has proven to be an effective treatment for recurrent Clostridioides difficile infection (rCDI) in both adult and pediatric patients. However, as microbiome development is a critical factor in children, it remains unclear whether adult fecal donors can provide …

In a Healio video exclusive, Lindy Bancke, PharmD, outlines results from the “largest safety evaluation to date” for Rebyota, the first FDA-approved, microbiota-based treatment for prevention of recurrent Clostridioides difficile infection. “There is a significant patient, health care provider and financial burden to address the continued dysbiosis, or disruption of the gut

Further studies are needed to provide robust recommendations for diagnosis, grading severity, and therapeutic management of CDI in cancer patients. Recurrences are particularly concerning due to subsequent exposition to CDI risk factors.

Alimentary Pharmacology & Therapeutics is a global pharmacology journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems

Nature Microbiology - Walker and Hoyles highlight selected myths and misconceptions in the human microbiota literature.

***

Objectives: An analysis of the weight and blood glucose management associated with fecal microbiota transplantation (FMT) as well as metabolic diseases associated with FMT was conducted by the authors in order to provide clinical recommendations regarding the treatment of nonalcoholic fatty l …

Patients with ACD exhibited differences in gut microbial composition and function relative to healthy controls. WMT is an effective treatment for ACD that reshapes gut microbial composition, restores butyrate-producing bacteria and regulates the functions of gut microbiota.

In the last decade, the role of the microbiota-gut-brain axis has been gaining momentum in the context of many neurodegenerative and metabolic disorders, including Alzheimer's disease (AD) and diabetes, respectively. Notably, a balanced gut microbiota contributes to the epithelial intestinal barrier …

Given the impact of the gut microbiome on human physiology and aging, it is possible that the gut microbiome may affect locomotion in the same way as the host's own genes. There is not yet any direct evidence linking the gut microbiome to locomotion, though there are some potential connections, such …

gov , date of registration 08/08/2019.

Microbiome-based therapeutics for Clostridioides difficile infection: helpful solutions or unclear cocktails?

The partnership between Cordlife and AMILI is the first-of-its-kind, with the aim of providing transformative healthcare solutions to patients in Singapore and Southeast Asia

Porcine epidemic diarrhea virus (PEDV) infection poses a significant threat to the global pig industry. Current prevention and control strategies are inadequate in protecting pigs from new PEDV variants. This review aims to examine the relationship between PEDV and intestinal microbes, and investiga …

PARSIPPANY, N.J., July 11, 2023--Largest Integrated Safety Analysis for REBYOTA Published in Therapeutic Advances in Gastroenterology.

As an important sequela of the burgeoning global obesity problem, metabolic-associated fatty liver disease (MAFLD) has gained increasing prominence recently. The gut-liver axis (GLA) provides a direct conduit to the liver for the gut microbiota and their metabolic by-products (including secondary bi …

Despite the effect on the gut microbiome, we did not observe robust improvement in patients' liver function or HE cognition tests after the procedure.

Clostridioides difficile is one of the most important causes of healthcare-associated diarrhea. The high incidence and recurrence rates of C. difficile infection, as well as its associated morbidity and mortality, are great concerns. The most common complication of C. difficile infection is recurren …

Human Microbiome Community Forum

Overall, MaaT013 was safe in this population of highly immunocompromised patients and was associated with responses in some patients with GI-aGvHD and deserves further investigation.